Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CDK-IN-6, a pyrazolo[1,5-a]pyrimidine compound, exhibits potent anticancer activities as a CDK inhibitor[1].
Description | CDK-IN-6, a pyrazolo[1,5-a]pyrimidine compound, exhibits potent anticancer activities as a CDK inhibitor[1]. |
In vitro | CDKs, including CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, among others, play specific roles in the progression of the cell cycle, being categorized into G1, S, or G2M phase enzymes. The unchecked proliferation characteristic of cancer cells often involves the frequent misregulation of CDK function in various significant solid tumors[1]. |
Molecular Weight | 380.49 |
Formula | C21H28N6O |
CAS No. | 779353-02-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (131.41 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CDK-IN-6 779353-02-5 CDK IN 6 CDKIN6 inhibitor inhibit